Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$156.45 USD

156.45
13,991,025

+5.79 (3.84%)

Updated Aug 25, 2026 04:04 PM ET

After-Market: $156.65 +0.20 (0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (103 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

The Zacks Analyst Blog Highlights Alphabet, IBM, Merck, SandRidge Energy and NeurAxis

by Zacks Equity Research

Zacks highlights Alphabet, IBM, Merck, SandRidge Energy, and NeurAxis, providing research insights on their growth prospects, market performance, and key risks for investors.

Mark Vickery headshot

Top Research Reports for Alphabet, IBM & Merck

by Mark Vickery

Alphabet, IBM, and Merck headline Zacks' latest research reports, with insights spanning AI, cloud growth, and pipeline challenges.

Zacks Equity Research

MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer

by Zacks Equity Research

Merck and Daiichi's raludotatug deruxtecan wins FDA Breakthrough tag for treating CDH6 expressing platinum-resistant ovarian, primary peritoneal or fallopian tube cancers.

Zacks Equity Research

Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Kinjel Shah headshot

Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects

by Kinjel Shah

Pfizer's late-stage pipeline, from oncology blockbusters to mRNA vaccines, positions it for long-term growth despite recent setbacks.

Ekta Bagri headshot

BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?

by Ekta Bagri

Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.

Zacks Equity Research

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Merck (MRK) concluded the recent trading session at $85.11, signifying a +1.28% move from its prior day's close.

Kinjel Shah headshot

Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?

by Kinjel Shah

Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.

Ekta Bagri headshot

Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?

by Ekta Bagri

Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.

Kinjel Shah headshot

J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum

by Kinjel Shah

J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.